☆ 4.8 Review

Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis

FRONTIERS IN IMMUNOLOGY (2023)

Related references

Note: Only part of the references are listed.

Review Clinical Neurology

Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis

Francesco Sacca et al.

Summary: This study conducted a meta-analysis and network meta-analysis of randomized and placebo-controlled trials to evaluate the efficacy of innovative therapies in myasthenia gravis (MG). The results showed that anti-complement and FcRn treatments were effective in MG patients, while rituximab did not provide significant benefit.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Add to Collection

Article Clinical Neurology

Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study

James F Howard et al.

LANCET NEUROLOGY (2023)

Add to Collection

Review Geriatrics & Gerontology

Comparative efficacy and safety of antidepressant therapy for the agitation of dementia: A systematic review and network meta-analysis

Kaili Chen et al.

Summary: Dementia is a common clinical syndrome in elderly individuals, and agitation, as a neuropsychiatric symptom, has a serious impact on the quality of life of dementia patients. This study conducted a network meta-analysis to examine the efficacy and safety of different antidepressant drugs in treating agitated behavior symptoms in dementia patients.

FRONTIERS IN AGING NEUROSCIENCE (2023)

Add to Collection

Article Endocrinology & Metabolism

Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease

George J Kahaly et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2023)

Add to Collection

Article Pharmacology & Pharmacy

Efgartigimod: First Approval

Young-A Heo

Summary: Efgartigimod is a novel drug developed by argenx for the treatment of autoimmune diseases, including myasthenia gravis. It received its first approval in the USA in 2021 and is currently being evaluated and registered in other countries. Numerous clinical studies are also investigating the use of Efgartigimod in various other autoimmune diseases.

DRUGS (2022)

Add to Collection

Article Clinical Neurology

Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis The BeatMG Study

Richard J. Nowak et al.

Summary: This study suggests that rituximab is safe but unlikely to significantly reduce steroid use in patients with mild to moderate symptoms of AChR-Ab+ gMG.

NEUROLOGY (2022)

Add to Collection

Review Clinical Neurology

Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases

Panos Stathopoulos et al.

Summary: B cells play an important role in the etiology of autoimmune neurological disorders, acting as antigen-presenting cells and regulating the immune response. Depletion of B cells has become a promising treatment strategy. This paper summarizes the basic aspects of B cell biology, discusses the roles of B cells in neurological autoimmunities, and highlights the efficacy and practical considerations of anti-B cell therapies in different neurological disorders.

NEUROTHERAPEUTICS (2022)

Add to Collection

Review Pharmacology & Pharmacy

Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals

Deepak Menon et al.

Summary: Myasthenia gravis is an autoimmune disorder that affects the neuromuscular junctions, leading to a wide range of symptoms. Traditional treatment options have weak evidence, while newer biological agents offer more targeted and effective therapy.

DRUGS (2022)

Add to Collection

Article Clinical Neurology

Eculizumab versus rituximab in generalised myasthenia gravis

Christopher Nelke et al.

Summary: This retrospective, observational study provides the first real-world evidence supporting the use of eculizumab for the treatment of refractory, anti-AChR-ab positive MG. However, despite better efficacy, the risk of MC remains high.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2022)

Add to Collection

Review Clinical Neurology

Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options

Rachel Zeng et al.

Summary: Inflammatory myopathies, or myositis, are rare diseases characterized by progressive muscle weakness, with each subtype having different autoantibody profiles, histological findings, and extramuscular manifestations. New molecular pathways for targeted therapy have been discovered due to a better understanding of the muscle inflammation's pathogenesis in myositis. Current therapies aim at different components of the immune response, and therapeutical antibodies have shown promising results in clinical trials.

NEUROTHERAPEUTICS (2022)

Add to Collection

Article Clinical Neurology

Therapeutic Effects of Batoclimab in Chinese Patients with Generalized Myasthenia Gravis: A Double-Blinded, Randomized, Placebo-Controlled Phase II Study

Chong Yan et al.

Summary: This study investigated the safety and potential efficacy of batoclimab in Chinese patients with generalized myasthenia gravis (gMG). The results showed that batoclimab was effective in improving the clinical symptoms of gMG and was well-tolerated by patients.

NEUROLOGY AND THERAPY (2022)

Add to Collection

Article Health Care Sciences & Services

The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis

Jeffrey A Tice et al.

Journal of Managed Care & Specialty Pharmacy (2021)

Add to Collection

Review Medicine, General & Internal

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Matthew J. Page et al.

Summary: The PRISMA statement was designed to help systematic reviewers transparently report the purpose, methods, and findings of their reviews. The updated PRISMA 2020 statement includes new reporting guidance, a 27-item checklist, an abstract checklist, and revised flow diagrams for reviews.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Clinical Neurology

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT) : a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Jr Jr Howard et al.

Summary: The study evaluated the safety and efficacy of efgartigimod in patients with generalised myasthenia gravis, showing that it was well tolerated and efficacious. The unique feature of individualized dosing based on clinical response in the study will provide further insights into clinical practice with longer term data from the ongoing open-label extension.

LANCET NEUROLOGY (2021)

Add to Collection

Review Medicine, General & Internal

Rituximab in the Management of Refractory Myasthenia Gravis and Variability of Its Efficacy in Anti-MuSK Positive and Anti-AChR Positive Myasthenia Gravis

Sanjiv Bastakoti et al.

Summary: Myasthenia gravis affects the neuromuscular junction leading to muscle weakness. Treatment options such as azathioprine, corticosteroids, plasma exchange, and tacrolimus may not be effective in some cases. Rituximab has shown to be effective in refractory myasthenia gravis cases, reducing corticosteroid dependence and inducing sustained remission.

CUREUS JOURNAL OF MEDICAL SCIENCE (2021)

Add to Collection

Article Clinical Neurology

Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial

James F. Howard et al.

JAMA NEUROLOGY (2020)

Add to Collection

Review Immunology

Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics

Konstantinos Lazaridis et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

CINeMA: An approach for assessing confidence in the results of a network meta-analysis

Adriani Nikolakopoulou et al.

PLOS MEDICINE (2020)

Add to Collection

Review Oncology

Monoclonal Antibody-Based Therapies for Myasthenia Gravis

Sawsan Alabbad et al.

BIODRUGS (2020)

Add to Collection

Article Clinical Neurology

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

James F. Howard et al.

NEUROLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Myasthenia gravis

Nils Erik Gilhus et al.

NATURE REVIEWS DISEASE PRIMERS (2019)

Add to Collection

Review Hematology

Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics

Christopher J. Patriquin et al.

TRANSFUSION MEDICINE REVIEWS (2019)

Add to Collection

Article Medicine, General & Internal

Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia A Network Meta-analysis

Ismaeel Yunusa et al.

JAMA NETWORK OPEN (2019)

Add to Collection

Review Clinical Neurology

B CELLS IN THE PATHOPHYSIOLOGY OF MYASTHENIA GRAVIS

John S. Yi et al.

MUSCLE & NERVE (2018)

Add to Collection

Article Clinical Neurology

Generalized Myasthenia Gravis: Classification, Clinical Presentation, Natural History, and Epidemiology

Michael K. Hehir et al.

NEUROLOGIC CLINICS (2018)

Add to Collection

Article Clinical Neurology

Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis

Karen Hewett et al.

NEUROLOGY (2018)

Add to Collection

Article Medicine, Research & Experimental

Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration

Bryan Smith et al.

MABS (2018)

Add to Collection

Article Clinical Neurology

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard et al.

LANCET NEUROLOGY (2017)

Add to Collection

Review Medicine, General & Internal

Facilitation roles and characteristics associated with research use by healthcare professionals: a scoping review

Lisa A. Cranley et al.

BMJ OPEN (2017)

Add to Collection

Article Clinical Neurology

Myasthenia gravis incidence in a general North Atlantic isolated population

P. Joensen

ACTA NEUROLOGICA SCANDINAVICA (2014)

Add to Collection

Review Immunology

Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4

Jan J. G. M. Verschuuren et al.

AUTOIMMUNITY REVIEWS (2013)

Add to Collection

Article Multidisciplinary Sciences

Graphical Tools for Network Meta-Analysis in STATA

Anna Chaimani et al.

PLOS ONE (2013)

Add to Collection

Review Rheumatology

B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies

Maria J. Leandro

ARTHRITIS RESEARCH & THERAPY (2013)

Add to Collection

Article Mathematical & Computational Biology

Automating network meta-analysis

Gert van Valkenhoef et al.

RESEARCH SYNTHESIS METHODS (2012)

Add to Collection

Article Clinical Neurology

ANTI-MuSK ANTIBODY MYASTHENIA GRAVIS: CLINICAL FINDINGS AND RESPONSE TO TREATMENT IN TWO LARGE COHORTS

Jeffrey T. Guptill et al.

MUSCLE & NERVE (2011)

Add to Collection

Review Immunology

B-Cell-Activating Factor and Autoimmune Myasthenia Gravis

Samia Ragheb et al.

AUTOIMMUNE DISEASES (2011)

Add to Collection

Article Medicine, General & Internal

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Julian P. T. Higgins et al.

BMJ-BRITISH MEDICAL JOURNAL (2011)

Add to Collection

Review Clinical Neurology

Lifetime course of myasthenia gravis

David Grob et al.

MUSCLE & NERVE (2008)

Add to Collection

Editorial Material Medicine, General & Internal

GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations

Gordon H. Guyatt et al.

BRITISH MEDICAL JOURNAL (2008)

Add to Collection

Article Statistics & Probability

Bayesian measures of model complexity and fit

DJ Spiegelhalter et al.

JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.